Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01198028 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma
A Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 42
- Enrollment target
- 1
- Study location
NCT01198028 is a Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 42 participants, below the 58-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (28% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01198028, a Phase 2 study of Metastatic Skin Squamous Cell Carcinoma and Recurrent Skin Squamous Cell Carcinoma, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 42 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back. Drugs used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Conditions Studied
Interventions
- DRUG Erlotinib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2011-03-10 |
| Est. Completion | 2019-05-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01198028
The ClinicalTrials.gov registry entry for NCT01198028 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 58-participant average among 5 other Metastatic Skin Squamous Cell Carcinoma trials with a reported enrollment target (28% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Metastatic Skin Squamous Cell Carcinoma appearing as the primary indexed condition, and to 1 intervention - of which Erlotinib is the first listed.
NCT01198028 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01198028 about?
NCT01198028 is a clinical study titled "Erlotinib in Treating Patients With Recurrent or Metastatic Skin Squamous Cell Carcinoma". This phase II trial studies how well erlotinib works in treating participants with skin squamous cell carcinoma that has spread to other places in the body or has come back. Drugs used in chemotherapy, such as erlotinib, work in different ways to stop the growth of tumor cells, either by killing the...
What is the current status of trial NCT01198028?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 42 participants. The study started on 2011-03-10. Estimated completion is 2019-05-01.
What conditions does trial NCT01198028 study?
This clinical trial studies the following conditions: Metastatic Skin Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma.
What interventions are being tested in trial NCT01198028?
The interventions under investigation include: Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01198028?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01198028 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Skin Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treatment With Amivantamab and Hyaluronidase or Cetuximab for Advanced Skin Cancer in People With a Weakened Immune System
RECRUITING · Phase 2
-
Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic
ACTIVE NOT RECRUITING · Phase 2
-
Cemiplimab Before and After Surgery for the Treatment of High Risk Cutaneous Squamous Cell Cancer
RECRUITING · Phase 1
-
Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
RECRUITING · Phase 1
-
Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Metastatic Skin Squamous Cell Carcinoma
All registered trials for this condition
Recurrent Skin Squamous Cell Carcinoma
All registered trials for this condition
Texas
All trials with a study site in Texas
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.